Researchers

HAYASHI Hidetoshi

HAYASHI Hidetoshi
Professor/Senior Staff
Faculty Department of Medicine / Graduate School of Medical Sciences
Researchmap https://researchmap.jp/hayashi_h

Education and Career

Education

  • 1997/04 - 2003/03 , Osaka University, Faculty of Medicine,
  • 2009/04 - 2012/03 , Kindai University, Faculty of Medicine,

Academic & Professional Experience

  • Apr. 2023 - Today , Kindai University, Faculty of Medicine Department of Medical Oncology Professor
  • Apr. 2022 - Today , Kindai University, Faculty of Medicine Department of Medical Oncology 特命准教授
  • Apr. 2020 - Mar. 2022 , 近畿大学医学部 内科学腫瘍内科 講師
  • Oct. 2015 - Mar. 2020 , Kindai university hospital Department of Medical Oncology Lecturer
  • Apr. 2015 - Sep. 2015 , Kindai university hospital Department of Medical Oncology Assistant professor
  • Apr. 2013 - Mar. 2015 , Kishiwada City Hospital Department of Medical Oncology Director
  • Apr. 2009 - Mar. 2013 , Kindai university hospital Department of Medical Oncology assistant professor
  • Apr. 2006 - Mar. 2009 , Kurashiki Central Hospital Respiratory Medicine Medical Staff
  • Apr. 2003 - Mar. 2006 , Sumitomo Hospital General Medicine Resident

Research Activities

Research Areas

  • Life sciences, Tumor diagnostics and therapeutics

Research Interests

Cancer of Unknown Primary, Lung Cancer, Gene analysis, medical oncology, immune checkpoint inhibitor

Published Papers

  1. Figure S1 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
    Kimio Yonesaka; Junko Tanizaki; Osamu Maenishi; Koji Haratani; Hisato Kawakami; Kaoru Tanaka; Hidetoshi Hayashi; Kazuko Sakai; Yasutaka Chiba; Asuka Tsuya; Hiroki Goto; Eri Otsuka; Hiroaki Okida; Maki Kobayashi; Ryoto Yoshimoto; Masanori Funabashi; Yuuri Hashimoto; Kenji Hirotani; Takashi Kagari; Kazuto Nishio; Kazuhiko Nakagawa
    24, Nov. 2025 
  2. Figure S3 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
    Kimio Yonesaka; Junko Tanizaki; Osamu Maenishi; Koji Haratani; Hisato Kawakami; Kaoru Tanaka; Hidetoshi Hayashi; Kazuko Sakai; Yasutaka Chiba; Asuka Tsuya; Hiroki Goto; Eri Otsuka; Hiroaki Okida; Maki Kobayashi; Ryoto Yoshimoto; Masanori Funabashi; Yuuri Hashimoto; Kenji Hirotani; Takashi Kagari; Kazuto Nishio; Kazuhiko Nakagawa
    24, Nov. 2025 
  3. Figure S4 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
    Kimio Yonesaka; Junko Tanizaki; Osamu Maenishi; Koji Haratani; Hisato Kawakami; Kaoru Tanaka; Hidetoshi Hayashi; Kazuko Sakai; Yasutaka Chiba; Asuka Tsuya; Hiroki Goto; Eri Otsuka; Hiroaki Okida; Maki Kobayashi; Ryoto Yoshimoto; Masanori Funabashi; Yuuri Hashimoto; Kenji Hirotani; Takashi Kagari; Kazuto Nishio; Kazuhiko Nakagawa
    24, Nov. 2025 

MORE

Conference Activities & Talks

  1. Prognostic impact of EMT-related genes on post-operative prognosis in hepatocellular carcinoma. , 永井 知行; 荒尾 徳三; 松本 和子; 藤田 至彦; 林 秀敏; 木村 英晴; 萩原 智; 櫻井 俊治; 上嶋 一臣; 土師 誠二; 工藤 正俊; 西尾 和人 , AACR 103rd Annual Meeting 2011 , Mar. 2012
  2. 進行肺腺癌を対象としたゲフィチニブ／S-1併用療法第１層臨床試験 , 清田 秀美; 岡本 勇; 田中 薫; 林 秀敏; 寺嶋応顕; 東 公一; 武田真幸; 米阪 仁雄; 藤阪 保仁; 鶴谷 純司; 宮﨑 昌樹; 佐藤 太郎; 倉田 宝保; 中川 和彦 , 第51回日本肺癌学会総会 , Nov. 2010
  3. 進行肺腺癌を対象としたゲフェチニブ／S-1 併用療法第１相臨床試験 , 清田 秀美; 岡本 勇; 谷﨑 潤子; 文田 壮一; 岡本 邦男; 牧村 ちひろ; 竹澤 健; 田中 薫; 林 秀敏; 岡本 渉; 寺嶋応顕; 東 公一; 金田裕靖; 武田真幸; 上田 眞也; 米阪 仁雄; 藤阪 保仁; 鶴谷 純司; 宮﨑 昌樹; 佐藤 太郎; 倉田 宝保; 中川 和彦 , 第92回日本肺癌学会関西支部会 , Jul. 2010

MORE

MISC

  1. Drug Therapy Based on Cancer Genome Profiling (CGP, Comprehensive Genomic Profiling) in Lung Cancer , 川中雄介; 米阪仁雄; 米阪仁雄; 稲垣千昌; 稲垣千昌; 高濱隆幸; 高濱隆幸; 白石直樹; 坂井和子; 西尾和人; 中川和彦; 林秀敏 , 日本がん分子標的治療学会学術集会プログラム・抄録集 , 28th , 2024
  2. Classification of tissue origin of cancer by methylation profiling , 坂井和子; デベラスコ マルコ; 三谷誠一郎; 倉由吏恵; 源周治; 波江野高大; 林秀敏; 林秀敏; 西尾和人; 西尾和人 , 日本癌学会学術総会抄録集(Web) , 83rd , 2024
  3. Current Status and Issues of “imNET“ Activities of the Immune-Related Adverse Events Management Team in Kindai Hospital , 高濱隆幸; 磯本晃佑; 鈴木慎一郎; 渡邉諭美; 金村宙昌; 稲垣千晶; 三谷誠一郎; 谷崎潤子; 吉田健史; 田中薫; 川上尚人; 岩朝勤; 米阪仁雄; 藤原季美子; 萩原智; 西山理; 桑原基; 竹久志穂; 高橋直美; 林秀敏 , 日本臨床腫瘍学会学術集会(CD-ROM) , 21st , 2024

MORE

Patents

  1. 免疫チェックポイント阻害剤の奏効性の判定を補助する方法、試薬キット、装置及びコンピュータプログラム , 本庶 佑, 茶本 健司, 林 秀敏, 中川 和彦, 後藤 恵, 宇賀 均
  2. 免疫チェックポイント阻害剤の奏効性の判定を補助する方法、試薬キット、装置及びコンピュータプログラム , 本庶 佑, 茶本 健司, 林 秀敏, 中川 和彦, 後藤 恵, 宇賀 均 , 特許第7251738号

Awards & Honors

  1. Dec. 2022, 日本肺癌学会, 篠井・河合賞
  2. Jul. 2015, 日本臨床腫瘍学会, 日本臨床腫瘍学会奨励賞
  3. Jun. 2008, 西日本がん研究機構, 西日本がん研究機構賞

Research Grants & Projects

  1. Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Validation study of a model for estimating the primary organ of cancer of unknown primary by methylation analysis of circulating tumor DNA , Kindai University
  2. Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Validation study of a model to estimate the primary organ of cancer of unknown primary , Kindai University
  3. Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Analysis of the risk factors for the development and severity of immune-related adverse events by immune checkpoint inhibitors , Kindai University

MORE